WORLD LEADING PARASITOLOGY AND MYCOLOGY TEST KITS
RAPID LATERAL FLOW TEST FOR BRUCELLA CANIS NOW AVAILABLE
Q-TOX FACTOR-X ACTIVATOR RVV-X NOW AVAILABLE
COST EFFECTIVE VETERINARY DIAGNOSTICS NOW AVAILABLE
Featured Products
Our Product Ranges
Recieve our latest news
Sign up to our newsletterOur Company
With over 30 years of trading experience, Quadratech Diagnostics Limited has always been and remains committed to providing the highest quality state-of-the-art medical diagnostic and research products. Since the company was founded in 1990, we have expanded to encompass the following main areas: Haemostasis, Antigens, Antibodies and Toxins, Rapid and POC Tests, Parasitology and Veterinary.
Quadratech Diagnostics Limited is a corporate member of the Institute of Biomedical Scientists (IBMS) and the British Society for Haemostasis and Thrombosis (BSHT). We are a recognised supplier to the UK National Health Service (NHS), the Irish Health Service Executive (HSE), private laboratories, the UK pharmaceutical industry, and university research groups. Quadratech Diagnostics Limited became incorporated as a limited company in 1998 and is ISO 9001:2015 certified.
Our Product Brands
Latest News
Quadratech Diagnostics launches Factor-X Activator RVV-X globally
We are delighted to announce a global launch of Factor-X Activator RVV-X (50U) as the latest addition to the Q-TOX range of high quality toxins, antigens, antibodies, and virus-like particles (VLPs). Q-TOX RVV-X is a highly purified Factor X activating enzyme prepared from the Russell Viper Venom (Daboia russelii). Q-TOX RVV-X is available for research […]
Haemostasis January 2025 Journal Club
Keep informed about evolving science and clinical practice with our January 2025 compilation of the latest studies, guidelines, and perspectives in haemostasis. PERSPECTIVES & REVIEWS Albert CM. Oral anticoagulation in device patients with atrial high-rate episodes: Shared decision-making after ARTESIA and NOAH-AFNET-6. Circulation. 2024;150(18):1398-1400. doi:10.1161/CIRCULATIONAHA.124.068018 Bos MHA, van Diest RE, Monroe DM. Blood coagulation factor […]
Haemostasis November & December 2024 Industry News
Our round-up of the latest developments from across the haemostasis industry for November & December 2024, including key readouts at ASH2024 REGULATORY Vaderis Therapeutics’ VAD044 (AKT inhibitor) granted FDA Fast Track designation for the treatment of Hereditary Haemorrhagic Telangiectasia (HHT) (18 Nov) Kedrion Biopharma announced that the FDA approved the company’s manufacturing facility in Bolognana, […]
